11. Patients must have normal organ and bone marrow function measured within 7 days prior to administration of study treatment as defined below: i. Hemoglobin >/= 10.0 g/dL and no blood transfusions in the 7 days prior to entry. ii. Absolute neutrophil count (ANC) >/= 1.5 x 10^9/L iii. White blood cells (WBC) >3x10^9/L iv. No features suggestive of myelodysplastic syndrome/acute myeloid leukemia on peripheral blood smear v. Platelet count >/= 100 x 10^9/L vi. Total bilirubin </=1.5 x institutional upper limit of normal (ULN) (except for patients with known Gilbert's disease). vii. aspartate aminotransferase (serum glutamine oxaloacetic transminase) and alanine aminotransferase (serum glutamic pyruvic transaminase) </= 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be </= 5x ULN viii. Calculated creatinine clearance (Cockcroft-Gault Equation) >/= 40 mL/min.